Bayer Focuses on Partnerships
The Leverkusen-based chemical and agricultural conglomerate Bayer is feeling the full force of structural change in the agricultural sector and is responding by realigning strategically. To reduce the portfolio’s environmental footprint by 30% by 2030, the company is relying on external alliances. Its own early-stage development centers, such as the West Sacramento site, have given way to a collaboration with Ginkgo Bioworks to research microbial nitrogen fixation. In addition, Bayer is advancing biostimulants such as Ambition Complete Gen2 in partnership with the Spanish company Kimitec. While the Crop Science division generated adjusted EBITDA of EUR 4.188 billion in fiscal year 2025, margin pressure in the conventional crop protection sector is forcing management to implement tough cost-cutting measures. By the end of 2026, Bayer aims to save EUR 2.0 billion across the group and is increasingly shifting high-risk screening to specialized partners.
Bioceres Stumbles After Aggressive Expansion
The Argentine company Bioceres is pursuing a different strategy, combining genetic drought resistance with biological crop protection. The company’s flagship product is the transgenic HB4 trait derived from sunflower genes, which protects wheat and soybeans from drought and has been approved in growing countries such as the US, Argentina and Brazil. In addition, the company acquired the biopesticide specialists Rizobacter and Marrone Bio. However, this debt-financed expansion strategy proved to be a risky move in the volatile agricultural market. For the six months ending December 2025, Bioceres reported a net loss of USD 189.9 million following a foreclosure on collateral totaling USD 179.0 million. Due to the significant decline in equity to USD 106.6 million and serious breaches of loan covenants, auditors issued a warning.
MustGrow Biologics Harnesses the Power of the Mustard Plant
While Bioceres has run into difficulties, Canadian agricultural company MustGrow Biologics is pursuing a lean business model. The company harnesses the mustard plant to extract a potent active ingredient. This active ingredient treats harmful soil fungi, nematodes, and other pests entirely without synthetic chemicals. Its flagship soil biopesticide, the pre-registered TerraMG™, offers a fully natural alternative to conventional chemical treatments. The effectiveness of this plant-based approach has also impressed the industry. In December 2023, Bayer secured an exclusive license to market TerraMG™ in the EMEA region, with Bayer investing in all regulatory approval and development costs.
MustGrow estimates the total value, comprising an upfront payment, milestone payments, and development expenses funded by Bayer, at between USD 35 million and USD 40 million. For the Canadian company, the deal provides an ideal allocation of risk: Bayer is shouldering the toxicology studies and lengthy European regulatory approval processes, while MustGrow could later generate recurring licensing fees and product supply revenues. At the same time, MustGrow retains control over its banana business, where the active ingredient achieved control of the fungus Fusarium oxysporum in laboratory testing against the devastating Panama disease, Fusarium wilt TR4. MustGrow holds a comprehensive portfolio of granted and pending patents covering bio-based applications.
US Expansion and Organic Certifications Drive TerraSante™
In parallel with its collaboration with Bayer, MustGrow is advancing the direct marketing of its biological soil fertility product, TerraSante™, in North America. The product consists of plant-based proteins and carbohydrates, promotes root growth, and specifically activates beneficial soil microbes. All regulatory approvals have already been obtained in key states including California, Washington, Oregon, Idaho, Florida, Arizona, Georgia, Texas, Utah and Montana. In addition, TerraSante™ holds organic certifications in accordance with current standards. Commercial field trials with potato farmers in the state of Washington yielded such good results that MustGrow switched its contract manufacturing in Asia to continuous production.
MustGrow in Summary: Solid Balance Sheet Meets Operational Leverage
MustGrow demonstrates that innovative plant biotechnology can also be advanced using an asset-light model. For investors, this approach reduces risks and allows the MustGrow team to focus on what matters most. The stock has recently gained momentum. As fertilizers and chemicals also become increasingly expensive, MustGrow’s products provide an increasingly significant lever for securing agricultural yields and meeting regulatory requirements. The company is exciting, and the stock of this Bayer partner is a must-watch.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
